

**Additional information pursuant to Art. 33, para 1, item 7
of Ordinance 2 dated 17.09.2003 of
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.
as of 31 December 2017**

1. Information about the changes in the accounting policy during the reporting period, the reasons for their making and in what way they impact on the issuers financial result and equity.

The interim financial statements of Tchaikapharma High Quality Medicines Inc. have been prepared in accordance with International Financial Reporting Standards as adopted in the European Union.

More detailed information about the Company's accounting policies is disclosed in section II.1. Basis of preparation of the financial statements in the Notes to the interim financial statements for the period 01 January 2017 – 31 December 2017.

2. Information on the results from organizational changes within the issuer, such as transformation, selling of undertakings from the economic group, non-money contributions by the undertaking, renting out of property, long-term investments, suspension of operation

The carrying amount of investments in companies is as follows:

		<i>31.12.2017</i>	<i>Share</i>	<i>31.12.2016</i>	<i>Share</i>
		<i>BGN '000</i>	<i>%</i>	<i>BGN '000</i>	<i>%</i>
Tchaikapharma HQMAA Inc.	Bulgaria	1	1%	1	1%

3. Opinion of the management body about the likelihood of realization of the published forecasts on the results of the current financial year, taking account of the results of the current quarter, as well as information about the factors and circumstances which will influence the obtaining of the forecast results at least for the next quarter - no update of the projected results.

4. For the public companies - data about the persons holding directly or indirectly at least 5 per cent of the votes in the general meeting at the end of the relevant quarter, and the changes in the held by the persons votes for the period since the end of the preceding quarter:

SHAREHOLDERS	Shares	/%/	Shares	/%/
	31.12.2017		31.12.2016	
Tihomir Kamenov	61 538 834	/95.71%/	54 200 576	/95.76%/

5. Information on pending legal, administrative or arbitration procedures relating to liabilities or receivables at the rate of at least 10 per cent from the issuer's equity – none.

Biser Georgiev
Executive Director